{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:58:41Z","timestamp":1791597521794,"version":"4.3.4"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the impact of thyroid eye disease (TED) on patients in various stages of the disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>TED is a debilitating and potentially sight-threatening inflammatory autoimmune disease that is frequently misdiagnosed. Challenging quality-of-life (QoL) issues can persist long after the active phase of disease has subsided.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 62-question survey was designed as a hypothesis-generating instrument to identify key issues confronting patients \u226518 years old with physician-diagnosed TED. Questions focused primarily on physical and emotional status, and QoL experiences in the 2 months prior to the survey. Data for individual questions are presented as summary statistics. Correlations between questions were determined using \u03c7<jats:sup>2<\/jats:sup> analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 443 respondents were 18 to &amp;gt;80 years old; &amp;gt;90% female, and &amp;gt;80% from the United States. Time since TED diagnosis ranged from &amp;lt;1 year to &amp;gt;10 years. Participants provided &amp;gt;500 free-form responses describing experiences of living with TED. Physical signs\/symptoms were experienced by 307\/443 (69%) patients. Of those responding to the QoL questions (N = 394), 53 (13%) reported symptoms improving, 73 (19%) reported symptoms worsening, and 255 (65%) reported no change in the 2 months prior to the survey. The most bothersome signs\/symptoms were dry\/gritty eyes, light sensitivity, bulging eyes, and pressure or pain behind the eyes. Respondents &amp;lt;60 years were significantly (p &amp;lt; 0.0001) more likely to report symptomatic TED than older patients. Of 394 respondents, 179 (45%) reported feeling depressed and\/or anxious, 174 (44%) reported concern about their appearance, and 73 (19%) avoided public situations; 192 (49%) reported declines in confidence or feelings of general well-being, and 78 (20%) reported an inability to achieve goals. Activities limited by TED included reading, driving, and socializing. The proportion of respondents experiencing these negative QoL measures was higher when patients reported experiencing &amp;gt;5 symptoms, had been diagnosed within the last 5 years, or were &amp;lt;60 years of age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Physical manifestations of TED impact QoL for patients through all phases of the disease. It is essential that physicians and healthcare professionals become more familiar with patient experiences such as those described here to better help patients manage their disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1283374","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T04:00:51Z","timestamp":1699848051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["How patients experience thyroid eye disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Terry J.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Heged\u00fcs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Lesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Perros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Dorris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Kinrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patti","family":"Troy-Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Wuerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukund","family":"Nori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of Graves' orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac328","article-title":"Understanding pathogenesis intersects with effective treatment for thyroid eye disease","volume":"107","author":"Smith","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.06.003","article-title":"Inflammatory and noninflammatory thyroid eye disease: Comparison of disease signs, symptoms, and quality of life in patients in the United States","volume":"28","author":"Wang","year":"2022","journal-title":"Endocr Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves' orbitopathy as a rare disease in Europe: A European Group on Graves' Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves' disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: A consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0055","article-title":"Quality of life in thyroid eye disease: impact of quality of care","volume":"164","author":"Estcourt","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066711","article-title":"Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study","volume":"8","author":"Brandt","year":"2013","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0708","article-title":"Hyperthyroidism and psychiatric morbidity: evidence from a Danish nationwide register study","volume":"170","author":"Brandt","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1530\/EJE-15-0306","article-title":"Hyperthyroidism is associated with work disability and loss of labour market income: a Danish register-based study in singletons and disease-discordant twin pairs","volume":"173","author":"Brandt","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0365","article-title":"Death by suicide in Graves' disease and Graves' orbitopathy: a nationwide Danish register study","volume":"27","author":"Ferlov-Schwensen","year":"2017","journal-title":"Thyroid"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0954","article-title":"Mortality in Graves' orbitopathy is increased and influenced by gender, age and pre-existing morbidity: a nationwide Danish register study","volume":"176","author":"Schwensen","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-021-00385-8","article-title":"Quality of life in patients with chronic thyroid eye disease in the United States","volume":"10","author":"Cockerham","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.3225","article-title":"Utility assessment of moderate to severe thyroid eye disease health states","volume":"141","author":"Smith","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002318","article-title":"Evaluation of depression and anxiety in a diverse population with thyroid eye disease using the nationwide NIH All of Us database","volume":"39","author":"Lee","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40123-020-00318-x","article-title":"Physician-perceived impact of thyroid eye disease on patient quality of life in the United States","volume":"10","author":"Wang","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0383","article-title":"The patient experience of services for thyroid eye disease in the United Kingdom: results of a nationwide survey","volume":"161","author":"Estcourt","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.03087.x","article-title":"The impact of thyroid eye disease upon patients' wellbeing: a qualitative analysis","volume":"68","author":"Estcourt","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bjo-2022-322442","article-title":"Presentation of Graves' orbitopathy within European Group on Graves' Orbitopathy (EUGOGO) centres from 2012 to 2019 (Prego III)","author":"Schuh","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac230","article-title":"Measuring health-related quality of life in thyroid eye disease","volume":"107","author":"Sharma","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1002\/edm2.357","article-title":"Thyroid disease-specific quality of life questionnaires - a systematic review","volume":"5","author":"Uslar","year":"2022","journal-title":"Endocrinol Diabetes Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-300487","article-title":"Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease","volume":"95","author":"Fayers","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0521","article-title":"Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO","volume":"162","author":"Watt","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1322","article-title":"The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects","volume":"99","author":"Watt","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0026","article-title":"Determining minimal important change for the thyroid-related quality of life questionnaire ThyPRO","volume":"10","author":"Nordqvist","year":"2021","journal-title":"Endocr Connect"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.82.7.773","article-title":"Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: The GO-QOL","volume":"82","author":"Terwee","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2007.0069","article-title":"Which domains of thyroid-related quality of life are most relevant? Patients and clinicians provide complementary perspectives","volume":"17","author":"Watt","year":"2007","journal-title":"Thyroid"},{"key":"B30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-319-99713-1_5","article-title":"The EU's General Data Protection Regulation (GDPR) in a research context","volume-title":"Fundamentals of clinical data science","author":"Mondschein","year":"2019"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0665","article-title":"Knowledge of thyroid eye disease in Graves' disease patients with and without orbitopathy","volume":"29","author":"Edmunds","year":"2019","journal-title":"Thyroid"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/01676830.2017.1280057","article-title":"Management of thyroid eye disease in the United Kingdom: A multi-centre thyroid eye disease audit","volume":"36","author":"Mellington","year":"2017","journal-title":"Orbit"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-306733","article-title":"Prego (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group on Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012","volume":"99","author":"Perros","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.88.1.75","article-title":"Assessing quality of life in Australian patients with Graves' ophthalmopathy","volume":"88","author":"Park","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7602419","article-title":"Evaluation of the Graves' Orbitopathy-Specific Quality of Life questionnaire in the mainland Chinese population","volume":"2019","author":"Zeng","year":"2019","journal-title":"J Ophthalmol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0172","article-title":"A survey on the management of thyroid eye disease among American and European Thyroid Association members","volume":"32","author":"Brito","year":"2022","journal-title":"Thyroid"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad084","article-title":"Factors predicting long-term outcome and the need for surgery in graves orbitopathy: Extended follow-up from the CIRTED trial","volume":"108","author":"Taylor","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0411","article-title":"The effect of ophthalmic surgery for graves' orbitopathy on quality of life: A systematic review and meta-analysis","volume":"32","author":"Woo","year":"2022","journal-title":"Thyroid"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2011.11.001","article-title":"Quality of life in Graves' ophthalmopathy","volume":"26","author":"Wiersinga","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1283374\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T04:00:53Z","timestamp":1699848053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1283374\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":39,"alternative-id":["10.3389\/fendo.2023.1283374"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1283374","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"article-number":"1283374"}}